Use of Non-Benzo Sleeping Pills and Anti-Epilepsy Drugs Linked to Overdose Deaths | Columbia Public Health – Columbia University's Mailman School of Public Health

See Coronavirus Updates for information on campus protocols. Booster documentation is due by February 28, 2022.
With an alarming rise in the number of prescriptions filled for non-benzodiazepine sleeping pills/z-drugs and anti-epilepsy gabapentinoids over the last two decades, researchers at Columbia University Mailman School of Public Health examined overdose deaths involving those medications and learn more about their co-usage with other substances. They found that the proportion of overdose deaths involving these drugs increased more than three-fold between 2000 and 2018, coinciding with exponential prescription increases since their introduction into the market. Until now there was little data on overdose deaths involving non-benzodiazepines and gabapentinoids. The findings are published in The Lancet Regional Health- Americas.
More than 67 percent of those who died from overdoses with these drugs between 2000 and 2018 had also opioids in their system, indicating that using more than one substance is the norm.
“These drug classes were introduced as less dangerous alternatives to opioids and benzodiazepines, creating perceptions among physicians and patients of their supposed increased safety, even without guidelines or data to back up such perceptions and leading to increases in prescribing,” said Silvia Martins, MD, PhD, professor of epidemiology and senior author. “Approved for short-term treatment of insomnia, they were touted as safe alternatives to the popular benzodiazepines when introduced to the market as less prone to abuse or dependence. Yet, recent evidence suggests that this alternative may also be as harmful as the product it is intended to replace. We felt it was critical to further explore and especially determine the dangers of their co-usage.”
The researchers used data from the National Center for Health Statistics to calculate the overdose death rate per 100,000 persons for every year between 2000 and 2018.
Between 2000 and 2018, 788,135 persons died with an overdose code as the underlying cause of death. Of those, 587,884 persons had any specific T code indicating that a drug was involved among their multiple causes of death. Furthermore, 21,167 among them had a T42.6/T42.7 code, which includes gabapentinoids and z-drugs. 
There were more intentional overdoses and a greater proportion of women, a greater share of whites, and those with higher educational attainment who died from an overdose between 2000 and 2018 with a T code of T42.6/T42.7 compared to the population of overall overdose casualties.
In addition to being prescribed to avoid or replace benzodiazepines and opioids, gabapentinoids are often offered off-label for such conditions as anxiety and insomnia. “The rise in gabapentin prescriptions roughly accompanies the involvement of z-drugs and gabapentinoids in overdose deaths, which suggests they can be playing a role in those deaths. The literature also has shown increasing deaths with gabapentin co-using with other substances including alcohol,” noted Martins.
Prescription opioids and benzodiazepines are the most common medication classes involved in drug-related emergency department visits and drug overdose deaths in the U.S. When taken in excess, both benzodiazepines and prescription opioids promote respiratory decline.
Despite the introduction of z-drugs and gabapentinoids aiming to replace benzodiazepines and opioids as safer alternatives to treat insomnia and pain, there exists sufficient evidence that users of one often add benzodiazepines and/or opioids, a dangerous and often fatal practice, according to the researchers.
“The positive news is that clinicians garnered some awareness about the risks of opioids after the catastrophic consequences of their widespread use, and prescriptions have decreased notably over the past 10 years,” said Vitor Tardelli, of the Universidade Federal de São Paulo and Centre for Addiction and Mental Health, Toronto, as well as a former Columbia Mailman school student. “Drug monitoring initiatives have already been implemented successfully to reduce prescribing of benzodiazepines as well.” However, he notes that illegal markets are a growing source of benzodiazepines—often with unclear potency. 
“Rates of concurrent overdose deaths with opioids and benzodiazepines are startling, and the involvement of gabapentinoids and z-drugs suggests they could add risk to non-medical users of benzodiazepines and opioids rather than minimize it. As such, gabapentinoids and z-drugs should always be prescribed with caution and patients should be monitored closely,” observed Tardelli. 
“Clinicians and primary care doctors should take a thorough history of potentially risky behaviors prior to prescribing these drugs and educate their patients about potential interactions between gabapentinoids and z-drugs with opioids, alcohol, and other sedative drugs,” said Martins.
Co-authors are Marina C. M. Bianco and Thiago M. Fidalgo, Universidade Federal de São Paulo;  Rashmika Prakash,, Luis E. Segura, and João M. Castaldelli-Maia, Columbia Mailman School.
Martins was funded by an internal grant from the Columbia University President’s Global Innovation Fund.
Columbia University Irving Medical Center
Copyright © Columbia University 2019

source

Add a Comment

Your email address will not be published.